Last update 01 Nov 2024
Ziarco, Inc.

Ziarco, Inc.

Subsidiary Company|
2012|
California, United States
|
< 10
|
www.ziarcopharma.com

Overview

Basic Info

Introduction
Ziarco is a pharmaceutical firm that specializes in creating drugs to combat inflammatory and allergic disorders. The company was established in 2012 and has its headquarters in Palo Alto, California.

Tags

Congenital Disorders
Immune System Diseases
Skin and Musculoskeletal Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases1
Top 5 Drug TypeCount
Small molecule drug1
Top 5 TargetCount
PLA2(Phospholipases A2)1

Related

2
Drugs associated with Ziarco, Inc.
ZPL-5212372
Target
PLA2
Mechanism
PLA2 inhibitors
Active Org.
Ziarco, Inc.Ziarco, Inc. [+1]
Originator Org.
Pfizer Inc.Pfizer Inc.
Active Indication
Dermatitis, Atopic
Inactive Indication
Asthma [+1]
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
ZPL-868087
Target
H3 receptor
Mechanism
H3 receptor antagonists
Active Org.-
Originator Org.
Pfizer Inc.Pfizer Inc.
Active Indication-
Inactive Indication
Rhinitis, Allergic
Drug Highest PhasePending
First Approval Ctry. / Loc.-
First Approval Date-
100 Clinical Results associated with Ziarco, Inc.
Login to view more data
0 Patents (Medical) associated with Ziarco, Inc.
Login to view more data
100 Deals associated with Ziarco, Inc.
Login to view more data
100 Translational Medicine associated with Ziarco, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
1
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
ZPL-5212372
 ( PLA2 )		Dermatitis, Atopic
More
Phase 2
ZPL-868087
 ( H3 receptor )		Rhinitis, Allergic
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free